TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18277214
Drug: Hemiplegia rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemiplegia rehabilitation program with analgesic and calcitonin therapy, elevation, range of movement therapy, and contrast baths.
Study: 18277214
Drug: Hemiplegia rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemiplegia rehabilitation program without additional therapies (control group).
Study: 1435930
Drug: Amoxicillin for
Normalized name: Amoxicillin for Oral Suspension
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin for 10 days
Study: 8653989
Drug: Phenobarbital (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbital (100 mg/day for 16 days)
Study: 29183956
Drug: G-formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-formula
Study: 20855823
Drug: mGEMOX (gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mGEMOX (gemcitabine 900 mg/m2 and oxaliplatin 80 mg/m2 IV infusion on days 1 and 8 every 3 weeks for maximum of six cycles)
Study: 20855823
Drug: FUFA (fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUFA (fluorouracil 425 mg/m2 and folinic acid 20 mg/m2 IV bolus weekly for 30 weeks)
Study: 17912635
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg once daily for 5 years
Study: 16376645
Drug: No antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antioxidant supplements
Study: 11568777
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (ccHRT)
Study: 10729965
Drug: Exercise in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise in combination with manual lymph drainage
Study: 9127079
Drug: Intra-articular instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular instillation of 20 mL bupivacaine (0.25%) and local infiltration of 20 mL bupivacaine (0.5%)
Study: 9127079
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution injection
Study: 1436589
Drug: Defibrotide, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defibrotide, 400 mg b.i.d. i.m.
Study: 1436589
Drug: Heparin calcium,
Normalized name: heparin calcium,porcine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin calcium, 5000 IU b.i.d. s.c.
Study: 3466089
Drug: Aminoglycoside solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminoglycoside solution
Study: 3466089
Drug: Oral antianaerobic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antianaerobic clindamycin
Study: 30922377
Drug: Calcitriol 0.5
Normalized name: CALCITRIOL 0.5MCG CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol 0.5 mcg daily for three months
Study: 30922377
Drug: Cholecalciferol 1000
Normalized name: cholecalciferol 1000 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol 1000 IU daily for three months
Study: 30371299
Drug: Fenofibrate 145
Normalized name: fenofibrate 145 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenofibrate 145 mg/d for 24 weeks
Study: 25440794
Drug: ALDH(br) cells
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALDH(br) cells delivered by direct intramuscular injections
Study: 18958560
Drug: 80 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/m2 paclitaxel administered weekly
Study: 15908042
Drug: Neo-adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neo-adjuvant chemotherapy (mitomycin, ifosfamide and cisplatin (MIC) or mitomycin, vinblastine and cisplatin (MVP)) followed by surgery (CT-S)
Study: 11796917
Drug: Maintenance chemotherapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance chemotherapy post-ASCT
Study: 10615229
Drug: Docetaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel (100 mg/m2 every 3 weeks, n = 143)
Study: 10615229
Drug: Sequential methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sequential methotrexate and 5-fluorouracil (MF; 200 mg/m2 and 600 mg/m2 every 3 weeks, n = 139)
Study: 7532395
Drug: Krypton laser
Normalized name: krypton (81mKr) gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton laser treatment covering the foveal side with a narrow (< or = 100 microns) border of treatment to adjacent uninvolved retina.
Study: 7532395
Drug: Krypton laser
Normalized name: krypton (81mKr) gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton laser treatment with either some of the foveal side of the lesion left untreated or a wide border of treatment on the foveal side.
Study: 7532395
Drug: Krypton laser
Normalized name: krypton (81mKr) gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton laser treatment in eyes with neovascular lesions 200 to 500 microns from the center of the foveal avascular zone.
Study: 7532395
Drug: Krypton laser
Normalized name: krypton (81mKr) gas
Approvals — FDA: no, EMA: no, PMDA: no
Description: Krypton laser treatment in eyes with lesions in either distance category in the Age‐Related Macular Degeneration Study.
Study: 31414974
Drug: Sufficient 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufficient 25(OH)D levels (30-100 ng/mL)
Study: 31414974
Drug: Active vitiligo
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vitiligo (associated with 25(OH)D deficiency ≤20 ng/mL)
Study: 31414974
Drug: Active vitiligo
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active vitiligo (associated with 25(OH)D insufficiency 21-29 ng/mL)
Study: 31414974
Drug: Stable vitiligo
Normalized name: Heat stable ricin vaccine
DrugBank: Heat stable ricin vaccine (DB18477)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable vitiligo (associated with sufficient 25(OH)D levels 30-100 ng/mL)
Study: 20609546
Drug: Entertainment-based decision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entertainment-based decision aid for breast cancer treatment along with usual care
Study: 17878636
Drug: 50/50 premixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50/50 premixed insulin lispro twice-daily
Study: 17878636
Drug: premixed human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: premixed human insulin (control group)
Study: 15520061
Drug: Intravenous vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vinorelbine (VRL) 30 mg/m2 on days 1 and 8 every 3 weeks plus hydrocortisone 40 mg/day
Study: 15520061
Drug: Intravenous vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vinorelbine (VRL) plus hydrocortisone
Study: 3381992
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g dipyrone
Study: 3381992
Drug: 1.0 g
Normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 g dipyrone
Study: 3381992
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g dipyrone
Study: 3381992
Drug: 2.0 g
Normalized name: Fifty50 2.0 Glucose Meter
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 g dipyrone
Study: 31780037
Drug: Peppermint gel
Normalized name: Peppermint
DrugBank: Peppermint (DB10984)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peppermint gel applied three times a day for up to 14 days
Study: 25586335
Drug: Peak CK‐MB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peak CK‐MB ≥300 IU/L
Study: 21969009
Drug: Amlodipine (2.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (2.5-10 mg/d)
Study: 21969009
Drug: Lisinopril (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10-40 mg/d)
Study: 18240352
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention and medication
Study: 16538423
Drug: Infrared LED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infrared LED treatment (160 mW, 6 min, energy density 3.2 J/cm²)
Study: 11033843
Drug: BALF‐IL‐12 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: BALF‐IL‐12 in sarcoidosis patients (41.3 +/- 43.9 pg/ml)
Study: 11033843
Drug: BALF‐IL‐12 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: BALF‐IL‐12 in patients with active disease (71.3 +/- 54.3 pg/ml)
Study: 11033843
Drug: AM of
Normalized name: Balsam of Peru
DrugBank: Balsam of Peru (DB11482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AM of sarcoidosis (133 +/- 177 pg/ml)
Study: 1470243
Drug: 20% albumin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% albumin solution plus crystalline infusion fluids
Study: 1470243
Drug: Crystalline infusion
Normalized name: Mesembryanthemum crystallinum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline infusion fluids (control group)
Study: 19625715
Drug: Vi vaccine
Normalized name: TYPHIM Vi VACCINE INJ SYRINGE 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vi vaccine
Study: 25018097
Drug: Control (Hepatitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Hepatitis A vaccine)
Study: 28873320
Drug: Rhodiola rosea
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola rosea (RR) - SHR group (n = 10) ingested standardized extract SHR-5 (432 mg daily)
Study: 29786343
Drug: Liquid wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid wound dressing (treatment group)
Study: 24842866
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin (40 mg/m(2))
Study: 24842866
Drug: 3-weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-weekly cisplatin (100 mg/m(2))
Study: 22872200
Drug: Topical 1.5%
Normalized name: phenol topical 1.5% topical liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1.5% azithromycin twice a day for three days
Study: 22872200
Drug: Topical 1.5%
Normalized name: phenol topical 1.5% topical liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 1.5% azithromycin twice a day for three days then at bedtime for the rest of the month
Study: 20497146
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg od for 4 weeks
Study: 20497146
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg od for 4 weeks
Study: 6383113
Drug: Aminophylline (60-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (60-120 mg)
Study: 25560711
Drug: Valganciclovir (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir (900 mg/d)
Study: 25560711
Drug: Placebo (preemptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (preemptive therapy)
Study: 17051503
Drug: Ritonavir-boosted comparator
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted comparator protease inhibitor (CPI/r)
Study: 11340106
Drug: Beta-carotene capsules
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-carotene capsules (6 mg daily for 60 days)
Study: 11340106
Drug: Puréed papaya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puréed papaya (650 g daily for 60 days)
Study: 11340106
Drug: Grated carrots
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grated carrots (100 g daily for 60 days)
Study: 3305590
Drug: Topical folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical folate (2 daily applications)
Study: 3305590
Drug: Systemic folate
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic folate (2 daily doses)
Study: 24727022
Drug: MK-5172 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5172 (100 mg) with peginterferon and ribavirin
Study: 24727022
Drug: MK-5172 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5172 (200 mg) with peginterferon and ribavirin
Study: 24727022
Drug: MK-5172 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5172 (400 mg) with peginterferon and ribavirin
Study: 24727022
Drug: MK-5172 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5172 (800 mg) with peginterferon and ribavirin
Study: 24727022
Drug: MK-5172 (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5172 (400 mg) and (800 mg) with peginterferon and ribavirin
Study: 22952407
Drug: Local anaesthetic
Normalized name: Local anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anaesthetic (Bupivicaine) and steroid (Trimacinolone) injection (n=18)
Study: 21564061
Drug: Both therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapy process modalities
Study: 21564061
Drug: Enactment-based therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enactment-based therapy process
Study: 17073160
Drug: Herceptin therapy
Normalized name: Herceptin
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Herceptin therapy
Study: 1547763
Drug: CBZ-CR 800
Normalized name: CBZ
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBZ-CR 800 mg
Study: 1547763
Drug: CBZ-CR 1200
Normalized name: CBZ
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBZ-CR 1200 mg
Study: 1547763
Drug: CBZ-CR 1600
Normalized name: CBZ
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBZ-CR 1600 mg
Study: 1547763
Drug: CBZ-CR (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBZ-CR (all doses)
Study: 1547763
Drug: CBZ-CR 800
Normalized name: CBZ
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CBZ-CR 800 mg, 1200 mg, 1600 mg
Study: 25893979
Drug: Topical ketoprofen
Normalized name: ketoprofen Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketoprofen in Transfersome(®) gel (IDEA‐033) plus oral placebo
Study: 25893979
Drug: Oral ketoprofen
Normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ketoprofen plus TDT 064
Study: 25893979
Drug: TDT 064
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDT 064 plus oral placebo
Study: 19968904
Drug: First-generation statin
Normalized name: First-generation cephalosporins
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-generation statin cholesterol-lowering medication
Study: 18667204
Drug: EPA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA treatment (n=7503)
Study: 14738263
Drug: Gemcitabine 1250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine 1250 mg/m2 on day 1 and day 8 and Cisplatin 80 mg/m2 on day 1, administered every 3 weeks, followed by radiotherapy after chemotherapy.
Study: 9184183
Drug: Oral etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral etoposide phosphate 125 mg m(‐2) on days 1‐5 every 3 weeks, escalating to 175 mg m(‐2) from course 3 when possible
Study: 3891194
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride preparation 1
Study: 3891194
Drug: Potassium chloride
Normalized name: Potassium Chloride
DrugBank: Potassium chloride (DB00761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Potassium chloride preparation 2
Study: 24222839
Drug: Intravenous ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ivabradine (5 mg bolus over 30 s, followed by 5 mg infusion over 8 h)
Study: 30115103
Drug: Intravenous ivabradine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ivabradine
Study: 7682007
Drug: Psychopharmacological medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychopharmacological medication (withdrawn)
Study: 4036935
Drug: Aspirin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3 x 325 mg tablets)
Study: 4036935
Drug: Ibuprofen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1 x 600 mg tablet)
Study: 4036935
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 identical placebo tablets)
Study: 30898632
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate cream (GTN)
Study: 25724645
Drug: S-ketamine 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine 0.25 mg/kg orally
Study: 25724645
Drug: S-ketamine 0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine 0.125 mg/kg intravenously
Study: 23245993
Drug: Short-acting β(2)-agonists
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting β(2)-agonists (SABA)
Study: 23245993
Drug: Muscarinic antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Muscarinic antagonists (SAMA)
Study: 14688498
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers
Study: 1385603
Drug: ondansetron (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron (4 mg)
Study: 19468545
Drug: droperidol (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol (1.25 mg)
Study: 19468545
Drug: metoclopramide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoclopramide (10 mg)
Study: 9133308
Drug: Thrombolysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolysis with streptokinase 1.5 million IU plus oral aspirin 150 mg OD (n = 12)
Study: 6852623
Drug: D-penicillamine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-penicillamine (600 mg/day)
Study: 6852623
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate (5 mg/day)
Study: 6852623
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after D-penicillamine or medroxyprogesterone
Study: 27189284
Drug: Denosumab 60
Normalized name: denosumab 60 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab 60 mg subcutaneous dose
Study: 24589307
Drug: Intraperitoneal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal infusion of catumaxomab after complete resection of all macroscopic disease.
Study: 24589307
Drug: Intraperitoneal infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal infusion of catumaxomab with different total doses administered in each of the 2 arms.
Study: 21546443
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate (10 mg elemental zinc)
Study: 19057412
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment for 12 weeks
Study: 17948207
Drug: Conventional weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional weight loss treatment
Study: 17948207
Drug: Obese individuals
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Obese individuals not participating in weight loss treatment
Study: 30799396
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral prednisolone for 3 days (PSL 3)
Study: 30799396
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral prednisolone for 7 days (PSL 7)
Study: 30799396
Drug: Low-dose oral
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oral prednisolone (both groups)
Study: 26013187
Drug: febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: febuxostat 80 mg/day
Study: 26013187
Drug: febuxostat 40
Normalized name: febuxostat 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: febuxostat 40 mg/day
Study: 26013187
Drug: allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: allopurinol 300 mg/day
Study: 25411289
Drug: VA+ (white
Approvals — FDA: no, EMA: no, PMDA: no
Description: VA+ (white maize with 400 μg retinol activity equivalents in oil)
Study: 22464779
Drug: LAM +
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAM + ADV combination therapy
Study: 22464779
Drug: LAM mono-therapy
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM mono-therapy
Study: 22464779
Drug: ADV mono-therapy
Normalized name: tiotropium bromide mono
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADV mono-therapy
Study: 19387976
Drug: Time-delayed capsule
Normalized name: ascorbic acid Oral Capsule [C-Time]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-delayed capsule formulation with 20% HPMC
Study: 19387976
Drug: Time-delayed capsule
Normalized name: ascorbic acid Oral Capsule [C-Time]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-delayed capsule formulation with 24% HPMC
Study: 19387976
Drug: Time-delayed capsule
Normalized name: ascorbic acid Oral Capsule [C-Time]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-delayed capsule formulation with 35% HPMC
Study: 19387976
Drug: Nondisintegrating riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nondisintegrating riboflavin tablet (used in pulsed release study)
Study: 15330916
Drug: Duodenal bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal bolus infusions of 5 ml of acid
Study: 15330916
Drug: Duodenal bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal bolus infusions of normal saline
Study: 15330916
Drug: Ondansetron (5‐HT(3)
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron (5‐HT(3) receptor antagonist)
Study: 1607978
Drug: Epidural corticosteroids
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural corticosteroids (40 mg methylprednisolone acetate)